Relevant bibliographies by topics / Antiviral agents / Journal articles

Journal articles on the topic 'Antiviral agents'

To see the other types of publications on this topic, follow the link: Antiviral agents.
Author: Grafiati
Published: 4 June 2021
Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antiviral agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Watts, D. Heather. "ANTIVIRAL AGENTS." Obstetrics and Gynecology Clinics of North America 19, no. 3 (September 1992): 563–85. http://dx.doi.org/10.1016/s0889-8545(21)00376-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bryson, Yvonne J. "Antiviral Agents." Clinics in Chest Medicine 7, no. 3 (September 1986): 453–67. http://dx.doi.org/10.1016/s0272-5231(21)01115-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lee, Hoan Jong. "Antiviral Agents." Journal of the Korean Medical Association 41, no. 3 (1998): 301. http://dx.doi.org/10.5124/jkma.1998.41.3.301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

KEATING, MICHAEL R. "Antiviral Agents." Mayo Clinic Proceedings 67, no. 2 (February 1992): 160–78. http://dx.doi.org/10.1016/s0025-6196(12)61319-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reines, Eric D., and Peter A. Gross. "Antiviral Agents." Medical Clinics of North America 72, no. 3 (May 1988): 691–715. http://dx.doi.org/10.1016/s0025-7125(16)30766-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brown, Tricia J., Melody Vander Straten, and Stephen K. Tyring. "ANTIVIRAL AGENTS." Dermatologic Clinics 19, no. 1 (January 2001): 23–34. http://dx.doi.org/10.1016/s0733-8635(05)70227-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

HERMANS, PAUL E., and FRANKLIN R. COCKERILL. "Antiviral Agents." Mayo Clinic Proceedings 62, no. 12 (December 1987): 1108–15. http://dx.doi.org/10.1016/s0025-6196(12)62505-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Michelle Felicia, Yuan Seng Wu, and Chit Laa Poh. "Molecular Mechanisms of Antiviral Agents against Dengue Virus." Viruses 15, no. 3 (March 8, 2023): 705. http://dx.doi.org/10.3390/v15030705.

Full text
Abstract:
Dengue is a major global health threat causing 390 million dengue infections and 25,000 deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of a clinically approved antiviral against dengue virus (DENV) drive the urgent demand for the development of novel anti-DENV therapeutics. Various antiviral agents have been developed and investigated for their anti-DENV activities. This review discusses the mechanisms of action employed by various antiviral agents against DENV. The development of host-directed antivirals targeting host receptors and direct-acting antivirals targeting DENV structural and non-structural proteins are reviewed. In addition, the development of antivirals that target different stages during post-infection such as viral replication, viral maturation, and viral assembly are reviewed. Antiviral agents designed based on these molecular mechanisms of action could lead to the discovery and development of novel anti-DENV therapeutics for the treatment of dengue infections. Evaluations of combinations of antiviral drugs with different mechanisms of action could also lead to the development of synergistic drug combinations for the treatment of dengue at any stage of the infection.
APA, Harvard, Vancouver, ISO, and other styles
9

MATSUMOTO, Keizo. "6. Antiviral Agents." Japanese Journal of Medicine 28, no. 3 (1989): 419–21. http://dx.doi.org/10.2169/internalmedicine1962.28.419.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

ROBINS, ROLAND K. "Synthetic Antiviral Agents." Chemical & Engineering News 64, no. 4 (January 27, 1986): 28–40. http://dx.doi.org/10.1021/cen-v064n004.p028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Abdel-Haq, Nahed, Pimpanada Chearskul, Hossam Al-Tatari, and Basim Asmar. "New antiviral agents." Indian Journal of Pediatrics 73, no. 4 (April 2006): 313–21. http://dx.doi.org/10.1007/bf02825826.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Bean, Bonnie. "New antiviral agents." Clinical Microbiology Newsletter 11, no. 10 (May 1989): 73–76. http://dx.doi.org/10.1016/0196-4399(89)90032-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Mousavi Movahed, Seyed Majid, Hamed Akhavizadegan, Fatemeh Dolatkhani, Samaneh Akbarpour, Seyed Aria Nejadghaderi, Morvarid Najafi, Parmida Sadat Pezeshki, Akram Khalili Noushabadi, and Hoomaan Ghasemi. "Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study." PLOS ONE 18, no. 10 (October 11, 2023): e0292746. http://dx.doi.org/10.1371/journal.pone.0292746.

Full text
Abstract:
Background Acute kidney injury is a complication of COVID-19 and is associated with severity. Despite no specific antiviral treatment strategy, lopinavir/ritonavir and remdesivir have been used. Data on the association between AKI and receiving antiviral agents with outcomes in hospitalized patients with COVID-19 is scarce. We aimed to determine the incidence of AKI and its outcomes in COVID-19 patients with and without antiviral medications. Methods We conducted a retrospective study on hospitalized adult patients with SARS-CoV-2 infection in a tertiary center. The primary endpoint was determining mortality, intensive care unit (ICU) admission, and length of hospitalization affected by AKI development using antiviral agents. The logistic regression method was used to explore the predictive effects of AKI and antiviral therapy on composite outcomes (i.e., mortality, ICU admission, and prolonged hospitalization) in four defined groups by AKI development/not and utilizing antivirals/not. We used IBM SPSS version 24.0 software for statistical analysis. Results Out of 833 COVID-19 patients who were included, 75 patients were treated with antiviral agents and developed AKI. There was a significant difference in the occurrence of AKI and using antiviral medications (p = 0.001). Also, the group using antiviral agents and the development of AKI had the highest rate of preexisting hypertension (p = 0.002). Of note, the group of patients who used antiviral agents and also developed AKI had the most remarkable association with our composite outcome (p<0.0001), especially ICU admission (OR = 15.22; 95% CI: 8.06–27.32). Conclusions The presence of AKI among COVID-19 patients treated with antiviral agents is linked to increased severity and mortality. Therefore, it is imperative to explore preventive measures for AKI development in patients receiving antiviral therapy. Larger-scale randomized controlled trials may be warranted to provide a more comprehensive understanding of these associations.
APA, Harvard, Vancouver, ISO, and other styles
14

Styrt, Barbara, and Joel P. Freiman. "HEPATOTOXICITY OF ANTIVIRAL AGENTS." Gastroenterology Clinics of North America 24, no. 4 (December 1995): 839–52. http://dx.doi.org/10.1016/s0889-8553(21)00230-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Mochulskaya, Nataliya N., Emiliya V. Nosova, and Valery N. Charushin. "Antiviral Agents – Benzazine Derivatives." Chemistry of Heterocyclic Compounds 57, no. 4 (April 2021): 374–82. http://dx.doi.org/10.1007/s10593-021-02915-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Lynd, Larry D., Ron Goeree, and Bernie J. O???Brien. "Antiviral Agents for Influenza." PharmacoEconomics 23, no. 11 (2005): 1083–106. http://dx.doi.org/10.2165/00019053-200523110-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Brown, Tricia J., Monica McCrary, and Stephen K. Tyring. "Antiviral agents: Nonantiviral drugs." Journal of the American Academy of Dermatology 47, no. 4 (October 2002): 581–99. http://dx.doi.org/10.1067/mjd.2002.121033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

THORNE, H. V. "Approaches to Antiviral Agents." Biochemical Society Transactions 14, no. 5 (October 1, 1986): 990–91. http://dx.doi.org/10.1042/bst0140990a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Caserta, Mary T., and Caroline Breese Hall. "Antiviral Agents for Influenza." Pediatric Annals 29, no. 11 (November 1, 2000): 704–11. http://dx.doi.org/10.3928/0090-4481-20001101-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Tanaka, Hideo, Kaori Nagao, and Satoru Ikeda. "Basis of antiviral agents:." Folia Pharmacologica Japonica 130, no. 2 (2007): 147–51. http://dx.doi.org/10.1254/fpj.130.147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

De Clercq, Erik. "Antiviral agents and immunity." Clinical Immunology Newsletter 6, no. 7 (July 1985): 103–7. http://dx.doi.org/10.1016/s0197-1859(85)80043-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Kaufman, Herbert E. "Update on Antiviral Agents." Ophthalmology 92, no. 4 (April 1985): 533–36. http://dx.doi.org/10.1016/s0161-6420(85)34011-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Kushner, Tatyana, and Vandana Khungar. "Direct-Acting Antiviral Agents." Clinics in Liver Disease 19, no. 4 (November 2015): 629–39. http://dx.doi.org/10.1016/j.cld.2015.06.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Eggers, Hans J. "Antiviral agents against picornaviruses." Antiviral Research 5 (January 1985): 57–65. http://dx.doi.org/10.1016/s0166-3542(85)80009-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Ilinskaya, O. N., and R. Shah Mahmud. "Ribonucleases as antiviral agents." Molecular Biology 48, no. 5 (September 2014): 615–23. http://dx.doi.org/10.1134/s0026893314040050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Johnson, James R. "Antiviral Agents for Influenza." JAMA 283, no. 23 (June 21, 2000): 3069. http://dx.doi.org/10.1001/jama.283.23.3068c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Lalani, Salima, and Chit Laa Poh. "Flavonoids as Antiviral Agents for Enterovirus A71 (EV-A71)." Viruses 12, no. 2 (February 6, 2020): 184. http://dx.doi.org/10.3390/v12020184.

Full text
Abstract:
Flavonoids are natural biomolecules that are known to be effective antivirals. These biomolecules can act at different stages of viral infection, particularly at the molecular level to inhibit viral growth. Enterovirus A71 (EV-A71), a non-enveloped RNA virus, is one of the causative agents of hand, foot and mouth disease (HFMD), which is prevalent in Asia. Despite much effort, no clinically approved antiviral treatment is available for children suffering from HFMD. Flavonoids from plants serve as a vast reservoir of therapeutically active constituents that have been explored as potential antiviral candidates against RNA and DNA viruses. Here, we reviewed flavonoids as evidence-based natural sources of antivirals against non-picornaviruses and picornaviruses. The detailed molecular mechanisms involved in the inhibition of EV-A71 infections are discussed.
APA, Harvard, Vancouver, ISO, and other styles
28

Caruso, Anna, Jessica Ceramella, Domenico Iacopetta, Carmela Saturnino, Maria Vittoria Mauro, Rosalinda Bruno, Stefano Aquaro, and Maria Stefania Sinicropi. "Carbazole Derivatives as Antiviral Agents: An Overview." Molecules 24, no. 10 (May 17, 2019): 1912. http://dx.doi.org/10.3390/molecules24101912.

Full text
Abstract:
Viruses represent the most common cause of infectious diseases worldwide and those with rapid propagation and high infection rates cause human and animal pandemics. These fast-spreading diseases are generally treated with antiviral drugs but, often, drug resistance occurs because of the ability of the pathogens to mutate rapidly and become less susceptible to the treatments. Even though new antivirals have been approved, e.g., in HIV (human immunodeficiency virus) and HCV (hepatitis C virus) therapeutic areas, the need to dispose of new pharmaceutical tools for the management of infections that still have no treatment is of growing interest. In these areas, carbazole represents an important privileged scaffold in drug discovery. Many compounds with a carbazolic core have been developed and some of them have shown antiviral activity. This review provides an overview on some already known carbazole derivatives, pointing the attention on the running progresses in identifying new molecules with carbazolic structure, that have shown interesting and encouraging in vitro and in vivo properties. These drugs may be exploited as valid alternatives in antiviral therapy.
APA, Harvard, Vancouver, ISO, and other styles
29

Gonzalez, M. E., B. Alarcon, and L. Carrasco. "Polysaccharides as antiviral agents: antiviral activity of carrageenan." Antimicrobial Agents and Chemotherapy 31, no. 9 (September 1, 1987): 1388–93. http://dx.doi.org/10.1128/aac.31.9.1388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Morahan, Page S., and Aangelo J. Pinto. "An Historic Overview of Biological Response Modifiers as Antiviral Agents." Canadian Journal of Infectious Diseases 3, suppl b (1992): 34–40. http://dx.doi.org/10.1155/1992/979517.

Full text
Abstract:
A wide variety ofimmunomodulators/biological response modifiers (BRMs) has been demonstrated to provide broad spectrum antiviral activity against both RNA and DNA viruses in several animal species. Dramatic decreases in mortality, reduced virus titres in tissues and reduced histopathology can be produced. The antivirally effective agents include microbially derived materials, polyanions, cytokines and chemically diverse small molecular weight chemicals. The greatest protective effects are observed with prophylactic treatment. although early therapeutic treatment can also be effective. Little direct antiviral activity can be observed in vitro. The findings suggest induction by BRMs of antiviral mediators in vivo early in the course of viral pathogenesis, before the virus has become sequestered in a privileged site or too much infectious virus has been produced for natural resistance to have an impact, immunomodulators are pleiotropic in their immunomodulatory effects, and it has been difficult to establish whether one cell type or mediator is critical for the observed broad spectrum antiviral activity. Therefore, the mechanisms of antiviral action of immunomodulators remain unclear for most systems, but probably involve enhancement of natural immune responses. While no unified antiviral mechanism among different immunomodulators has yet emerged, interferon induction remains a major hypothesis.
APA, Harvard, Vancouver, ISO, and other styles
31

Yuan, Shuofeng, Chris Chun-Yiu Chan, Kenn Ka-Heng Chik, Jessica Oi-Ling Tsang, Ronghui Liang, Jianli Cao, Kaiming Tang, et al. "Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)." Viruses 12, no. 6 (June 10, 2020): 628. http://dx.doi.org/10.3390/v12060628.

Full text
Abstract:
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
32

Smith, David, and David Speers. "Resistance to antiviral agents: balancing good and evil." Microbiology Australia 28, no. 4 (2007): 169. http://dx.doi.org/10.1071/ma07169.

Full text
Abstract:
Antiviral agents have been difficult to find and we still have only a handful that meet the safety and effectiveness we have come to expect from antibacterial agents. Some, because of these limitations, are reserved for serious conditions such as HIV, hepatitis B (HBV), hepatitis C and CMV in immunocompromised patients. The widespread use of antivirals has been a phenomenon of the last one to two decades, following on from the development of the nucleoside analogues for herpes viruses. Not unexpectedly, it is only in the very recent past that we have had to confront the problems of resistance of viruses to antiviral agents, though this already poses significant management problems for some conditions.
APA, Harvard, Vancouver, ISO, and other styles
33

Zusinaite, Eva, Aleksandr Ianevski, Diana Niukkanen, Minna Poranen, Magnar Bjørås, Jan Afset, Tanel Tenson, Vidya Velagapudi, Andres Merits, and Denis Kainov. "A Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents." Viruses 10, no. 8 (August 12, 2018): 423. http://dx.doi.org/10.3390/v10080423.

Full text
Abstract:
There are dozens of approved, investigational and experimental antiviral agents. Many of these agents cause serious side effects, which can only be revealed after drug administration. Identification of the side effects prior to drug administration is challenging. Here we describe an ex vivo approach for studying immuno- and neuro-modulatory properties of antiviral agents, which may be associated with potential side effects of these therapeutics. The current approach combines drug toxicity/efficacy tests and transcriptomics, which is followed by mRNA, cytokine and metabolite profiling. We demonstrated the utility of this approach with several examples of antiviral agents. We also showed that the approach can utilize different immune stimuli and cell types. It can also include other omics techniques, such as genomics and epigenomics, to allow identification of individual markers associated with adverse reactions to antivirals with immuno- and neuro-modulatory properties.
APA, Harvard, Vancouver, ISO, and other styles
34

İNCE KÖSE, Tuğçe, and Ayşe Mine GENÇLER ÖZKAN. "ANTIVIRAL HERBS." Ankara Universitesi Eczacilik Fakultesi Dergisi 46, no. 2 (May 29, 2022): 505–22. http://dx.doi.org/10.33483/jfpau.1057473.

Full text
Abstract:
Objective: Viruses are agents that can infect all kinds of living organisms, and the most important hosts are humans, animals, plants, bacteria and fungi. Viral diseases are responsible for serious morbidity and mortality worldwide, are a major threat to public health, and remain a major problem worldwide. The recently prominent Coronaviruses (CoVs) within this group belong to the Coronaviridae family, subfamily Coronavirinae, and are large (genome size 26−32 kb), enveloped, single-stranded ribonucleic acid (RNA ) viruses that can infect both animals and humans. The world has experienced three epidemics caused by betaCoVs in the last two decades: SARS in 2002−03, MERS in 2012, and COVID-19, first identified in 2019. COVID-19 continues to be our current health problem and studies on the subject continue.Result and Discussion: The term "antiviral agents" is defined in very broad terms as substances other than virus-containing vaccine or specific antibody that can produce a protective or therapeutic effect for the clearly detectable effect of the infected host.Nature has the potential to cure humanity's helplessness against viruses with many different plant species with strong antiviral effects. During the screening of plants with antiviral effects, focusing on plants used in folk medicine is of great importance in terms of maximizing the benefit to humanity - saving time and effort by dealing with valuable ancient knowledge on a scientific basis.In this review, viral diseases and the plants used in these diseases and determined to be effective are mentioned.
APA, Harvard, Vancouver, ISO, and other styles
35

Darby, Graham. "Optimism in antivirals Targets for the design of antiviral agents." Trends in Pharmacological Sciences 6 (January 1985): 380–81. http://dx.doi.org/10.1016/0165-6147(85)90178-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

De Moraes Gomes, Paulo André Teixeira, Lindomar J. Pena, and Ana C. Lima Leite. "Isatin Derivatives and Their Antiviral Properties Against Arboviruses: A Review." Mini-Reviews in Medicinal Chemistry 19, no. 1 (December 6, 2018): 56–62. http://dx.doi.org/10.2174/1389557518666180424093305.

Full text
Abstract:
Arboviruses have been spreading rapidly throughout the Western Hemisphere in recent decades. Among the arboviruses with high morbidity and mortality are the members of the Alphavirus and Flavivirus genera. Within the first genus, Chikungunya Virus (CHIKV) is considered one of the most challenging human arboviral infection worldwide, against which there is no specific antivirals. Flaviviruses are some of the main viruses responsible for encephalitis, haemorrhagic disease and developmental defects. Dengue virus (DENV), Japanese Encephalitis Virus (JEV), West Nile Virus (WNV) and Zika Virus (ZIKV) are examples of flaviviruses without clinically approved antiviral agents. Thus, the search for new antivirals becomes highly important. One of the strategies that can be employed to obtain new drugs is the identification and utilization of privileged structures. Isatin is an example of a privileged molecular framework, displaying a broad spectrum of biological activities, including antiviral action. Obtaining and studying the antiviral properties of isatin derivatives have helped to identify important agents with potential activity against different arboviruses. This article reviews some of these isatin derivatives, their structures and antiviral properties reported against this important group of viruses.
APA, Harvard, Vancouver, ISO, and other styles
37

Aloia, Amanda L., Stephen Locarnini, and Michael R. Beard. "Antiviral resistance and direct-acting antiviral agents for HCV." Antiviral Therapy 17, no. 6 Pt B (2012): 1147–62. http://dx.doi.org/10.3851/imp2426.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

SHIGETA, SHIRO, MITSUAKI HOSOYA, SHINOBU MOCHIZUKI, and TAKUO CHIBA. "Studies on Antiviral Agents. I. Antiviral Activity of Pyridobenzoazoles." YAKUGAKU ZASSHI 108, no. 9 (1988): 856–59. http://dx.doi.org/10.1248/yakushi1947.108.9_856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Hupp, James R. "Antibacterial, Antiviral, and Antifungal Agents." Oral and Maxillofacial Surgery Clinics of North America 3, no. 2 (May 1991): 273–85. http://dx.doi.org/10.1016/s1042-3699(20)30498-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Allen, Upton D., and Chaim M. Roifman. "Antiviral Agents, Vaccines, and Immunotherapies." Annals of Internal Medicine 142, no. 8 (April 19, 2005): 686. http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Vlietinck, A. J., T. De Bruyne, and D. A. Vanden Berghe. "Plant Substances As Antiviral Agents." Current Organic Chemistry 1, no. 4 (November 1997): 307–44. http://dx.doi.org/10.2174/1385272801666220126154627.

Full text
Abstract:
<p>Among the numerous compounds that have been reported to exhibit potent antiviral activity in cell cultures and/or in experimental animals are several natural products isolated from higher plants. Some of these plant compounds exhibit an unique antiviral mechanism and are good candidates for further clinical research. </p> <p> In this review, an approach to the isolation of potential antiviral plant agents and lead compounds is outlined. A discussion of plant selection, followed by a description of antiviral testing, both in vitro and in vivo, is also given. The importance of the plant kingdom as a source of potent antiviral lead substances will be illustrated by presenting a survey on plant-derived anti-herpes virus and anti-human immunodeficiency virus agents. </p>
APA, Harvard, Vancouver, ISO, and other styles
42

Park, Sehee, Jin Il Kim, and Man-Seong Park. "Antiviral Agents Against Influenza Viruses." Journal of Bacteriology and Virology 42, no. 4 (2012): 284. http://dx.doi.org/10.4167/jbv.2012.42.4.284.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

COULSON, JUDY, and ALAN D. B. MALCOLM. "Antisense oligonucleotides as antiviral agents." Biochemical Society Transactions 20, no. 2 (May 1, 1992): 213S. http://dx.doi.org/10.1042/bst020213s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

COULSON, JUDY M., NEIL W. BLAKE, LEONARD C. ARCHARD, and ALAN D. B. MALCOLM. "Antisense Oligodeoxynucleotides as antiviral agents." Biochemical Society Transactions 20, no. 4 (November 1, 1992): 321S. http://dx.doi.org/10.1042/bst020321s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

McKinlay, M. A., and M. G. Rossmann. "Rational Design of Antiviral Agents." Annual Review of Pharmacology and Toxicology 29, no. 1 (April 1989): 111–22. http://dx.doi.org/10.1146/annurev.pa.29.040189.000551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Adamson, Catherine S. "Antiviral Agents: Discovery to Resistance." Viruses 12, no. 4 (April 7, 2020): 406. http://dx.doi.org/10.3390/v12040406.

Full text
Abstract:
In the midst of the SARS-CoV-2/Covid-19 outbreak the need for research into, and development of, antiviral agents is brought into sharp focus worldwide for scientists, governments and the public alike [...]
APA, Harvard, Vancouver, ISO, and other styles
47

Patick, A. K., and K. E. Potts. "Protease Inhibitors as Antiviral Agents." Clinical Microbiology Reviews 11, no. 4 (October 1, 1998): 614–27. http://dx.doi.org/10.1128/cmr.11.4.614.

Full text
Abstract:
SUMMARY Currently, there are a number of approved antiviral agents for use in the treatment of viral infections. However, many instances exist in which the use of a second antiviral agent would be beneficial because it would allow the option of either an alternative or a combination therapeutic approach. Accordingly, virus-encoded proteases have emerged as new targets for antiviral intervention. Molecular studies have indicated that viral proteases play a critical role in the life cycle of many viruses by effecting the cleavage of high-molecular-weight viral polyprotein precursors to yield functional products or by catalyzing the processing of the structural proteins necessary for assembly and morphogenesis of virus particles. This review summarizes some of the important general features of virus-encoded proteases and highlights new advances and/or specific challenges that are associated with the research and development of viral protease inhibitors. Specifically, the viral proteases encoded by the herpesvirus, retrovirus, hepatitis C virus, and human rhinovirus families are discussed.
APA, Harvard, Vancouver, ISO, and other styles
48

Alymova, I., G. Taylor, and A. Portner. "Neuraminidase Inhibitors as Antiviral Agents." Current Drug Target -Infectious Disorders 5, no. 4 (December 1, 2005): 401–9. http://dx.doi.org/10.2174/156800505774912884.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Rawlinson, William. "Antiviral agents: advances and problems." British Journal of Clinical Pharmacology 53, no. 5 (May 2002): 542. http://dx.doi.org/10.1046/j.1365-2125.2002.01061.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Prince, Gregory A. "Respiratory syncytial virus antiviral agents." Expert Opinion on Therapeutic Patents 9, no. 6 (June 1999): 753–62. http://dx.doi.org/10.1517/13543776.9.6.753.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Antiviral agents' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography